Clinical Trial Results:
GAND-emesis: A multinational, randomized, double-blind, placebo-controlled, parallel-group study
to investigate the efficacy and tolerability of palonosetron and dexamethasone plus the neurokinin1-receptor antagonist, fosaprepitant dimeglumine or placebo in patients receiving radiotherapy and concomitant weekly cisplatin.
Summary
|
|
EudraCT number |
2009-014691-21 |
Trial protocol |
DK DE |
Global end of trial date |
24 Apr 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Sep 2021
|
First version publication date |
09 Sep 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
GAND-emesis
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01074697 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Odense University Hospital
|
||
Sponsor organisation address |
J. B. Winsløws vej 2, entrance 140, basement, Odense C, Denmark, 5000
|
||
Public contact |
Ida Coordt Elle, Odense University Hospital, 45 29335922, ida.coordt.elle@rsyd.dk
|
||
Scientific contact |
Christina Ruhlmann, Odense University Hospital, 45 22314446, christina.ruhlmann@rsyd.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 Nov 2015
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
24 Apr 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective is to compare an antiemetic regimen consisting of fosaprepitant dimeglumine (Ivemend®), palonosetron (Aloxi®), and dexamethasone (active arm) and a regimen consisting of palonosetron, dexamethasone, and placebo (control arm) with respect to efficacy; the proportion of subjects with no vomiting, i.e. sustained no emesis rate - during five weeks of fractionated (5 days a week) radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2.
|
||
Protection of trial subjects |
Only PS 0-2 included.
Patients were
excluded if they had other current malignant diagnoses
apart from non-melanoma skin cancers, total neutrophils
less than 1·5 × 10⁹ cells per L, platelets less than
100 × 10⁹ cells per L, bilirubin greater than 1·5 times
the upper limit of normal (ULN), and aspartate
aminotransferase or alanine aminotransferase greater
than 2·5 times the ULN.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Apr 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Norway: 8
|
||
Country: Number of subjects enrolled |
Denmark: 205
|
||
Country: Number of subjects enrolled |
Germany: 16
|
||
Country: Number of subjects enrolled |
Australia: 5
|
||
Worldwide total number of subjects |
234
|
||
EEA total number of subjects |
229
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
196
|
||
From 65 to 84 years |
38
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
Between June 15, 2010, and March 8, 2015, 246 patients from four countries consented to the study and were randomly assigned. Of these, 234 patients were eligible, having received study medication (118 received fosaprepitant, 116 received placebo). | |||||||||
Pre-assignment
|
||||||||||
Screening details |
Eligible patients were 18 years or older, had histologically confirmed cervical cancer, were scheduled to receive fractionated radiotherapy (1.8–2.0 Gy per fraction, five fractions per week to the pelvis) and concomitant weekly cisplatin 40 mg/m² for at least 5 weeks. | |||||||||
Period 1
|
||||||||||
Period 1 title |
Trial period (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Double blind | |||||||||
Roles blinded |
Subject, Investigator | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
Fosaprepitant | |||||||||
Arm description |
Patients were randomly assigned to receive single doses of fosaprepitant 150 mg intravenously in combination with palonosetron 0·25 mg intravenously and dexamethasone 16 mg orally before cisplatin administration. | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
Fosaprepitant
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for solution for infusion
|
|||||||||
Routes of administration |
Intravenous use
|
|||||||||
Dosage and administration details |
150mg i.v.
|
|||||||||
Investigational medicinal product name |
Palonosetron
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for solution for infusion
|
|||||||||
Routes of administration |
Intravenous use
|
|||||||||
Dosage and administration details |
0.25mg i.v.
|
|||||||||
Investigational medicinal product name |
Dexamethasone
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
16 mg
|
|||||||||
Arm title
|
Placebo | |||||||||
Arm description |
Patients were randomly assigned to receive single doses placebo (saline) in combination with palonosetron 0·25 mg intravenously and dexamethasone 16 mg orally before cisplatin administration. | |||||||||
Arm type |
Placebo | |||||||||
Investigational medicinal product name |
Placebo/saline
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for solution for infusion
|
|||||||||
Routes of administration |
Intravenous use
|
|||||||||
Dosage and administration details |
NA
|
|||||||||
Investigational medicinal product name |
Palonosetron
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for solution for infusion
|
|||||||||
Routes of administration |
Intravenous use
|
|||||||||
Dosage and administration details |
0.25mg i.v.
|
|||||||||
Investigational medicinal product name |
Dexamethasone
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
16 mg
|
|||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Fosaprepitant
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients were randomly assigned to receive single doses of fosaprepitant 150 mg intravenously in combination with palonosetron 0·25 mg intravenously and dexamethasone 16 mg orally before cisplatin administration. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients were randomly assigned to receive single doses placebo (saline) in combination with palonosetron 0·25 mg intravenously and dexamethasone 16 mg orally before cisplatin administration. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Fosaprepitant patients
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Patients allocated to Fosaprepitant
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Placebo patients
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Patients allocated to placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Fosaprepitant
|
||
Reporting group description |
Patients were randomly assigned to receive single doses of fosaprepitant 150 mg intravenously in combination with palonosetron 0·25 mg intravenously and dexamethasone 16 mg orally before cisplatin administration. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Patients were randomly assigned to receive single doses placebo (saline) in combination with palonosetron 0·25 mg intravenously and dexamethasone 16 mg orally before cisplatin administration. | ||
Subject analysis set title |
Fosaprepitant patients
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
Patients allocated to Fosaprepitant
|
||
Subject analysis set title |
Placebo patients
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
Patients allocated to placebo
|
|
|||||||||||||
End point title |
Proportion of patients with sustained no emesis | ||||||||||||
End point description |
The proportion of patients with sustained no emesis at 5 weeks (competing risk analysis).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
5 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Fine and Gray’s proportional subhazards model | ||||||||||||
Statistical analysis description |
The cumulative incidence of emesis was analysed using Fine and Gray’s proportional subhazards model (competing risk regression).Competing risk (other than patients with emesis, patients completing all five cycles without emesis, or censored events not due to emesis and not competing) was categorised as discontinuation for reasons of study treatment or for any reason.
|
||||||||||||
Comparison groups |
Placebo v Fosaprepitant
|
||||||||||||
Number of subjects included in analysis |
234
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
two-sided Pearson χ² test with continuit | ||||||||||||
Parameter type |
cumulative incidence | ||||||||||||
Point estimate |
60
|
||||||||||||
Confidence interval |
|||||||||||||
level |
80% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
50 | ||||||||||||
upper limit |
70 | ||||||||||||
Variability estimate |
Standard deviation
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
5 weeks
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
24.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Fosaprepitant
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients were randomly assigned to receive single doses of fosaprepitant 150 mg intravenously in combination with palonosetron 0·25 mg intravenously and dexamethasone 16 mg orally before cisplatin administration. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients were randomly assigned to receive single doses placebo (saline) in combination with palonosetron 0·25 mg intravenously and dexamethasone 16 mg orally before cisplatin administration. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/26952945 |